Dopa-decarboxylase inhibitor + dopamine precursor. ≥18yrs: Do not crush or chew. Patients not receiving levodopa: initially one Sinemet CR 50–200 tab twice daily, at intervals of at least 6 hrs.
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Carbidopa, Levodopa and Entacapone Tablets, 12.5 ...
Alembic Pharmaceuticals Ltd on Friday said it has received approval from the US health regulator for its generic version of ...
CREXONT ® is a novel, oral formulation of carbidopa/levodopa (CD/LD) capsule that combines both immediate-release granules and extended-release beads for the treatment of Parkinson’s disease. CREXONT ...
Alembic Pharmaceuticals has received U.S. Food and Drug Administration final approval for its abbreviated new drug application for Carbidopa, Levodopa and Entacapone Tablets in different strengths.
Alembic Pharmaceuticals receives USFDA approval for generic Carbidopa, Levodopa, and Entacapone tablets to treat Parkinson's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results